concurrent medication use, multiple drug use concurrent medication use, multiple drug use
Conditions
Interventions
The MMC that provides patient centred information on drug-drug interactions and
pharmacogenetics affecting personal polytherapy. The MMC will show a selection
of high quality publicly available info
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: • Polypharmacy defined as the use of 5 or more drugs • Start usage of at least one of 27 index drugs, for at least 7 con-secutive days. • Subject must be >= 18 years old • Subject is able and willing to take part and be followed-up for at least 12 weeks • Subject is able to provide DNA via blood, saliva or a buccal swab • Subject has signed informed consent
Exclusion criteria
Exclusion criteria: Pregnancy or lactating Life expectancy estimated to be less than three months by treating clinical team Unable to consent to the studyUnwilling to take partNo fixed addressPrevious (direct-to-consumer or clinical) pharmacogenetic testing for a gene relevant to the index drug.No current general practitioner Duration of treatment: Duration of index drug treatment is planned to be less than seven consecutive days. Impaired organ function:Existing impaired hepatic or renal function for which dose adjustment or alternative drug selection are already part of routine care. This does not apply to drugs specifically given to manage liver/renal impairment or transplantation.Estimated glomerular filtration rate (MDRD) of less than 15 ml/min per 1.73 m² in a subject with a functioning graft.Patients with advanced liver failure (Child-Pugh class C).Investigator judgement: The subject is, in the opinion of the Investigator, not suitable to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the sense of empowerment and health literacy for participants before and after use of the MMC. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes include an evaluation of the drug-drug-gene interactions and adverse drug events in the study populations compared to matched historical controls. | — |
Countries
Germany, Greece, Netherlands, Slovenia
Contacts
Public ContactJ.J. Swen
Leids Universitair Medisch Centrum
Outcome results
None listed